ES cells—E14Tg2a, EKOiE5 (link), EKOie–NrKO14 (link), FLAG–Nr5a2 (ref. 14 (link)), NR5A2–GFP/ESRRB–mCherry14 (link), ESRRB/NR5A2–GFP lines and ESRRB/NR5A2–IAA ESCs (see details below)—were cultured on serum and leukemia inhibitory factor conditions as previously described11 (link). Mitotic ES cells (>95% purity as assessed by 4′,6-diamidino-2-phenylindole staining and microscopy) were obtained using a double synchronization method based on the CDK1 inhibitor RO-3306 (10 μM; Sigma, SML0569), nocodazole (50 ng ml−1; Sigma, M1404) and shake-off, as previously described9 (link). For post-mitosis analyses, cells were seeded in separate dishes (one per time point), purposely uncoated with gelatin and lysed in cold TRIzol (ThermoFisher, 15596026) 20, 30, 40, 50, 60, 90 and 120 min after release from the mitotic block9 (link). ESRRB/NR5A2 depletion was achieved with 0.5 mM auxin (5-Ph-IAA BioAcademia, 30-003), added during the 5 h of nocodazole block and maintained during the whole post-mitotic release. Asynchronous cells were treated in parallel during 5 h.
Free full text: Click here